Upregulation of miR-21 in Cisplatin Resistant Ovarian Cancer via JNK-1/c-Jun Pathway
Open accessAbstract
Cisplatin has been the most accepted drug for the treatment of ovarian cancer for almost 40 years. Although the majority of patients with ovarian cancer respond to front-line platinum combination chemotherapy, many patients will develop cisplatin-resistance disease, which is extremely rapid and fatal. Although various mechanisms of cisplatin resistance have been postulated, the key molecules involved in such resistance have not been identified. MiRNAs are endogenously expressed small non-coding RNAs, which are evolutionarily conserved and function as post-transcriptional regulators of gene expression. Dysregulation of miRNAs have been associated with cancer initiation, progression and drug resistance. The oncogenic miRNA-21, one of the best-studied miRNAs, is upregulated in almost all human cancers. However, the regulation of miR-21 in cisplatin resistant ovarian cancer cells has not been assessed. In this study, we measured the miR-21 expression by real-time PCR and found upregulation of miR-21 in cisplatin resistant compared with cisplatin sensitive ovarian cancer cells. Chromatin immunoprecipitation studies demonstrated the association of the c-Jun transcription factor to the pri-mir-21 DNA promoter regions. Blocking the JNK-1, the major activator of c-Jun phosphorylation, reduced the expression of pre-mir-21 and increased the expression of its well-known target gene, PDCD4. Overexpression of miR-21 in cisplatin sensitive cells decreased PDCD4 levels and increased cell proliferation. Finally, targeting miR-21 reduced cell growth, proliferation and invasion of cisplatin resistant ovarian cancer cells. These results suggest that the JNK-1/c-Jun/miR-21 pathway contributes to the cisplatin resistance of ovarian cancer cells and demonstrated that miR-21 is a plausible target to overcome cisplatin resistance.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
miRNAs play a key role in the progression of malignant tumors and are considered potential anti-tumor therapeutic targets.
“miRNAs play a key role in the progression of malignant tumors, they are considered potential anti-tumor therapeutic targets24, 25.”
From miR-21-5p Inhibits the Proliferation, Migration, and Invasion of Glioma by Targeting S100A10 (2023) · cites this paper as [24]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
1 retracted
RETRACTED: The Role of microRNAs in the Tumorigenesis of Ovarian Cancer
Leva, G. D., & Croce, C. M. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00153 · Cited by 89 · see citing works
RetractedBartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714 · see citing works
Analyzing real-time PCR data by the comparative CT method
Schmittgen, T. D., & Livak, K. J. (2008) · Nature Protocols · doi:10.1038/nprot.2008.73 · Cited by 26,190 · see citing works
Siegel, R., Naishadham, D., & Jemal, A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21166 · Cited by 11,825 · see citing works
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927 · see citing works
Rubin, M., & Stephen, C. D. (1993) · Cited by 3,161 · see citing works
Molecular mechanisms of cisplatin resistance
Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., & Kroemer, G. (2012) · Oncogene · doi:10.1038/onc.2011.384 · Cited by 2,760 · see citing works
SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase
Bennett, B. L., Sasaki, D. T., Murray, B. W., O'Leary, E. C., Sakata, S. T., Xu, W., Leisten, J. C., Motiwala, A., Pierce, S., Satoh, Y., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251194298 · Cited by 2,558 · see citing works
The Regulation of AP-1 Activity by Mitogen-activated Protein Kinases
Karin, M. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.28.16483 · Cited by 2,432 · see citing works
Si, M.-L., Zhu, S., Wu, H., Lu, Z., Wu, F., & Mo, Y.-Y. (2007) · Oncogene · doi:10.1038/sj.onc.1210083 · Cited by 1,600 · see citing works
The biology of ovarian cancer: new opportunities for translation
Bast, R. C., Hennessy, B. T., & Mills, G. B. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2644 · Cited by 1,362 · see citing works
Yang, H., Kong, W. W., He, L., Zhao, J., O’Donnell, J. D., Wang, J., Wenham, R. M., Coppola, D., Kruk, P. A., Nicosia, S. V., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2488 · Cited by 1,051 · see citing works
miR‐21: a small multi‐faceted RNA
Krichevsky, A. M., & Gabriely, G. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00556.x · Cited by 987 · see citing works
MicroRNA Expression Profiles in Serous Ovarian Carcinoma
Nam, E. J., Yoon, H., Kim, S. W., Kim, H., Kim, Y. T., Kim, J., Kim, J. W., & Kim, S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1731 · Cited by 740 · see citing works
Peltier, H. J., & Latham, G. J. (2008) · RNA · doi:10.1261/rna.939908 · Cited by 716 · see citing works
Regulation and function of miRNA-21 in health and disease
Kumarswamy, R., Volkmann, I. R., & Thum, T. (2011) · RNA Biology · doi:10.4161/rna.8.5.16154 · Cited by 609 · see citing works
Behrens, B. C., Hamilton, T. C., Masuda, H., Grotzinger, K. R., Whang‐Peng, J., Louie, K. G., Knutsen, T., McKoy, W. M., Young, R. C., & Ozols, R. F. (1987) · PubMed · Cited by 501 · see citing works
Al‐Nasiry, S., Geusens, N., HANSSENS, M. C. A. J. A., Luyten, C., & Pijnenborg, R. (2007) · Human Reproduction · doi:10.1093/humrep/dem011 · Cited by 489 · see citing works
miR-21 Gene Expression Triggered by AP-1 Is Sustained through a Double-Negative Feedback Mechanism
Fujita, S., Ito, T., Mizutani, T., Minoguchi, S., Yamamichi, N., Sakurai, K., & Iba, H. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.03.015 · Cited by 432 · see citing works
Role of microRNAs in drug-resistant ovarian cancer cells
Sorrentino, A., Liu, C., Addario, A., Peschle, C., Scambia, G., & Ferlini, C. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.08.017 · Cited by 354 · see citing works
Clinical Applications for microRNAs in Cancer
Nana-Sinkam, S. P., & Croce, C. M. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.192 · Cited by 348 · see citing works
Differential regulation of c‐Jun by ERK and JNK during PC12 cell differentiation
Leppä, S., Saffrich, R., Ansorge, W., & Bohmann, D. (1998) · The EMBO Journal · doi:10.1093/emboj/17.15.4404 · Cited by 335 · see citing works
Curcumin regulates miR-21 expression and inhibits invasion and metastasis in colorectal cancer
Mudduluru, G., George-William, J. N., Muppala, S., Asangani, I. A., Kumarswamy, R., Nelson, L. D., & Allgayer, H. (2011) · Bioscience Reports · doi:10.1042/bsr20100065 · Cited by 332 · see citing works
MicroRNA-21: A novel therapeutic target in human cancer
Pan, X., Wang, Z.-X., & Wang, R. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.10.12.14252 · Cited by 322 · see citing works
Up-regulation of miR-21 Mediates Resistance to Trastuzumab Therapy for Breast Cancer
Gong, C., Yao, Y., Wang, Y., Liu, B., Wu, W. G., Chen, J., Su, F., Yao, H., & Song, E. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.216887 · Cited by 310 · see citing works
Ma, J., Dong, C., & Ji, C. (2010) · Cancer Gene Therapy · doi:10.1038/cgt.2010.18 · Cited by 303 · see citing works
MicroRNAs, macrocontrol: Regulation of miRNA processing
Ślęzak-Prochazka, I., Durmuş, S., Kroesen, B., & van den Berg, A. (2010) · RNA · doi:10.1261/rna.1804410 · Cited by 268 · see citing works
Molecular Determinants of Ovarian Cancer Plasticity
Sood, A. K., Seftor, E. A., Fletcher, M. S., Gardner, L. M. G., Heidger, P. M., Buller, R. E., Seftor, R. E. B., & Hendrix, M. J. C. (2001) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64079-5 · Cited by 268 · see citing works
An autoregulatory loop mediated by miR-21 and PDCD4 controls the AP-1 activity in RAS transformation
Talotta, F., Cimmino, A., Matarazzo, M. R., Casalino, L., De Vita, G., D'Esposito, M., Di Lauro, R., & Verde, P. (2009) · Oncogene · doi:10.1038/onc.2008.370 · Cited by 242 · see citing works
Wyman, S. K., Parkin, R. K., Mitchell, P. S., Fritz, B. R., O'Briant, K. C., Godwin, A. K., Urban, N. D., Drescher, C. W., Knudsen, B. S., & Tewari, M. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005311 · Cited by 233 · see citing works
miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells
van Jaarsveld, M. T. M., Helleman, J., Boersma, A. W. M., van Kuijk, P. F., van IJcken, W. F. J., Despierre, E., Vergote, I. B., Mathijssen, R. H. J., Berns, E., Verweij, J., et al. (2012) · Oncogene · doi:10.1038/onc.2012.433 · Cited by 219 · see citing works
Lou (2010) · International Journal of Molecular Medicine · doi:10.3892/ijmm_00000530 · Cited by 175 · see citing works
Peng, R.-Q., Wan, H., Li, H., Liu, M., Li, X., & Tang, H. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.337642 · Cited by 165 · see citing works
The inhibition of miR-21 promotes apoptosis and chemosensitivity in ovarian cancer
Chan, J. K., Blansit, K., Kiet, T. K., Sherman, A. E., Wong, G., Earle, C. A., & Bourguignon, L. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.01.034 · Cited by 142 · see citing works
Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies
Vasey, P. A. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601497 · Cited by 125 · see citing works
Derfoul, A., Juan, A. H., Difilippantonio, M. J., Palanisamy, N., Ried, T., & Sartorelli, V. (2011) · Carcinogenesis · doi:10.1093/carcin/bgr184 · Cited by 124 · see citing works
Imanaka, Y., Tsuchiya, S., Sato, F., Shimada, Y., Shimizu, K., & Tsujimoto, G. (2011) · Journal of Human Genetics · doi:10.1038/jhg.2011.1 · Cited by 100 · see citing works
Apte, S. M., Bucana, C. D., Killion, J. J., Gershenson, D. M., & Fidler, I. J. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2003.12.041 · Cited by 92 · see citing works
Loss of Programmed cell death 4 (Pdcd4) associates with the progression of ovarian cancer
Wei, N., Liu, S. S., Leung, T. H., Tam, K., Liao, X. Y., Cheung, A., Chan, K. K. L., & Ngan, H. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-70 · Cited by 79 · see citing works
The BRK tyrosine kinase is expressed in high-grade serous carcinoma of the ovary
Schmandt, R. E., Bennett, M., Clifford, S., Thornton, A., Jiang, F., Broaddus, R. R., Sun, C. C., Lu, K. H., Sood, A. K., & Gershenson, D. M. (2006) · Cancer Biology & Therapy · doi:10.4161/cbt.5.9.2953 · Cited by 78 · see citing works
Silencing Survivin Splice Variant 2B Leads to Antitumor Activity in Taxane-Resistant Ovarian Cancer
Vivas‐Mejía, P. E., Rodriguez‐Aguayo, C., Han, H., Shahzad, M. M. K., Valiyeva, F., Shibayama, M., Chávez‐Reyes, A., Sood, A. K., & Lopez‐Berestein, G. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0233 · Cited by 73 · see citing works
Self-citationc-Jun-NH2-kinase-1 Inhibition Leads to Antitumor Activity in Ovarian Cancer
Vivas‐Mejía, P. E., Benito, J. M., Fernandez, A., Han, H., Mangala, L. S., Rodriguez‐Aguayo, C., Chávez‐Reyes, A., Lin, Y. G., Carey, M. S., Nick, A. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1180 · Cited by 68 · see citing works
Self-citationAP-1-Dependent miR-21 Expression Contributes to Chemoresistance in Cancer Stem Cell-Like SP Cells
Misawa, A., Katayama, R., Koike, S., Tomida, A., Watanabe, T., & Fujita, N. (2010) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504010x12828372551759 · Cited by 65 · see citing works
XIE, Z., Cao, L., & Zhang, J. (2013) · Oncology Letters · doi:10.3892/ol.2013.1432 · Cited by 63 · see citing works
Micro-RNA-21 regulates the sensitivity to cisplatin in human neuroblastoma cells
Chen, Y., Tsai, Y., Yu, F., & Tseng, S. (2012) · Journal of Pediatric Surgery · doi:10.1016/j.jpedsurg.2012.05.013 · Cited by 48 · see citing works
Chen, Y., Zhang, L., & Hao, Q. (2013) · Cancer Cell International · doi:10.1186/1475-2867-13-86 · Cited by 43 · see citing works
Skilling, J. S., Squatrito, R. C., Connor, J. P., Niemann, T. H., & Buller, R. E. (1996) · Gynecologic Oncology · doi:10.1006/gyno.1996.0014 · Cited by 41 · see citing works
Braun, R., Finney, R., Yan, C., Chen, Q. R., Hu, Y., Edmonson, M. N., Meerzaman, D. M., & Buetow, K. H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055037 · Cited by 38 · see citing works
Lou, Y., Cui, Z., Wang, F., Yang, X., & Qian, J. (2011) · Clinical and investigative medicine · doi:10.25011/cim.v34i5.15671 · Cited by 26 · see citing works
Vivas‐Mejía, P. E., Özpolat, B., Chen, X., & Lopez‐Berestein, G. (2009) · International Journal of Cancer · doi:10.1002/ijc.24341 · Cited by 24 · see citing works
Self-citation[The mechanism of cisplatin-resistance in ovarian cancer].
Kikuchi, Y. (2001) · PubMed · Cited by 10 · see citing works
Assessment of mRNA Splice Variants by qRT-PCR
Vargas, I. M. E., & Vivas‐Mejía, P. E. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-547-7_13 · Cited by 9 · see citing works
Self-citation
Flagged first, then by citations
1 of the 53 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Emerging role of microRNA-21 in cancer
Feng, Y., & Tsao, C. (2016) · Biomedical Reports · doi:10.3892/br.2016.747 · Cited by 456 · see citing works
miRNAs: Potential as Biomarkers and Therapeutic Targets for Cancer
Chakrabortty, A., Patton, D. J., Smith, B. F., & Agarwal, P. (2023) · Genes · doi:10.3390/genes14071375 · Cited by 258 · see citing works
Linking the future of anticancer metal-complexes to the therapy of tumour metastases
Bergamo, A., & Sava, G. (2015) · Chemical Society Reviews · doi:10.1039/c5cs00134j · Cited by 220 · see citing works
Bioinformatic tools for microRNA dissection
Akhtar, M. M., Micolucci, L., Islam, M. S., Olivieri, F., & Procopio, A. D. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv1221 · Cited by 216 · see citing works
Hashemi, M., Mirdamadi, M. S. A., Talebi, Y., Khaniabad, N., Banaei, G., Daneii, P., Gholami, S., Ghorbani, A., Tavakolpournegari, A., Farsani, Z. M., et al. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2022.106568 · Cited by 153 · see citing works
Modulation of microRNA editing, expression and processing by ADAR2 deaminase in glioblastoma
Tomaselli, S., Galeano, F., Alon, S., Raho, S., Galardi, S., Polito, V. A., Presutti, C., Vincenti, S., Eisenberg, E., Locatelli, F., et al. (2015) · Genome biology · doi:10.1186/s13059-014-0575-z · Cited by 144 · see citing works
MiR-21: an environmental driver of malignant melanoma?
Melnik, B. C. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0570-5 · Cited by 129 · see citing works
Targeting c-MYC in Platinum-Resistant Ovarian Cancer
Reyes‐González, J. M., Armaiz-Peña, G. N., Mangala, L. S., Valiyeva, F., Ivan, C., Pradeep, S., Echevarría-Vargas, I. M., Rivera-Reyes, A., Sood, A. K., & Vivas‐Mejía, P. E. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0801 · Cited by 124 · see citing works
Self-citationMicroRNA in Ovarian Cancer: Biology, Pathogenesis, and Therapeutic Opportunities
Chen, S., Chang, R., Lin, L., Chern, C.-U., Tsai, H., Wen, Z., Li, Y.-H., Li, C., & Tsui, K. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16091510 · Cited by 123 · see citing works
Exosomes as mediators of platinum resistance in ovarian cancer
Crow, J., Atay, S., Banskota, S., Artale, B., Schmitt, S., & Godwin, A. K. (2017) · Oncotarget · doi:10.18632/oncotarget.14440 · Cited by 120 · see citing works
Ferraresi, A., Phadngam, S., Morani, F., Galetto, A., Alabiso, O., Chiorino, G., & Isidoro, C. (2016) · Molecular Carcinogenesis · doi:10.1002/mc.22582 · Cited by 117 · see citing works
Hu, Z., Cai, M., Zhang, Y., Tao, L., & Guo, R. (2019) · Cell Cycle · doi:10.1080/15384101.2019.1704537 · Cited by 117 · see citing works
Glutathione in Ovarian Cancer: A Double-Edged Sword
Nunes, S. C., & Serpa, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19071882 · Cited by 110 · see citing works
Brain Targeted Gold Liposomes Improve RNAi Delivery for Glioblastoma
Grafals‐Ruiz, N., Ríos-Vicil, C. I., Lozada-Delgado, E. L., Quiñones‐Díaz, B. I., Rivera, R. A. N., Martínez-Zayas, G., Santana‐Rivera, Y., Santiago-Sánchez, G. S., Valiyeva, F., & Vivas‐Mejía, P. E. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s241055 · Cited by 110 · see citing works
Self-citationMicroRNAs in gynecological cancers: Small molecules with big implications
Srivastava, S. K., Ahmad, A., Zubair, H., Miree, O., Singh, S., Rocconi, R. P., Scalici, J. M., & Singh, A. P. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.05.011 · Cited by 109 · see citing works
Targeting miR-21-3p inhibits proliferation and invasion of ovarian cancer cells
Báez-Vega, P. M., Vargas, I. M. E., Valiyeva, F., Encarnación-Rosado, J., Roman, A., Flores, J., Marcos-Martínez, M. J., & Vivas-Mejía, P. E. (2016) · Oncotarget · doi:10.18632/oncotarget.9216 · Cited by 107 · see citing works
Self-citationAn, Y., & Yang, Q. F. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.117162 · Cited by 85 · see citing works
Zou, J., Liu, L., Wang, Q., Yin, F., Yang, Z., Zhang, W., & Li, L. (2017) · PubMed Central · Cited by 71 · see citing works
The Role of Autophagy and Related MicroRNAs in Inflammatory Bowel Disease
Wang, S., Huang, Y., Zhou, C., Wu, H., Zhao, J., Wu, L., Zhao, M., Zhang, F., & Liu, H. (2018) · Gastroenterology Research and Practice · doi:10.1155/2018/7565076 · Cited by 70 · see citing works
Targeting strategies on miRNA-21 and PDCD4 for glioblastoma
Wang, G., Wang, J. J., Tang, H., & To, S. S. T. (2015) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2015.07.001 · Cited by 63 · see citing works
MicroRNAs in ovarian cancer and recent advances in the development of microRNA-based biosensors
Aziz, N. B., Mahmudunnabi, R. G., Umer, M., Sharma, S., Rashid, M. A., Alhamhoom, Y., Shim, Y., Salomón, C., & Shiddiky, M. J. A. (2020) · The Analyst · doi:10.1039/c9an02263e · Cited by 57 · see citing works
MiR-490-3p sensitizes ovarian cancer cells to cisplatin by directly targeting ABCC2.
Tian, J., Xu, Y., Li, L., & Hao, Q. (2017) · PubMed Central · Cited by 56 · see citing works
Exosome‑mediated gefitinib resistance in lung cancer HCC827 cells via delivery of miR‑21
Jing, C., Cao, H., Qin, X., Yu, S., Wu, J., Wang, Z., Ma, R., & Feng, J. (2018) · Oncology Letters · doi:10.3892/ol.2018.8604 · Cited by 56 · see citing works
MicroRNAs as the critical regulators of Cisplatin resistance in ovarian cancer cells
Moghbeli, M. (2021) · Journal of Ovarian Research · doi:10.1186/s13048-021-00882-1 · Cited by 57 · see citing works
The Roles of microRNAs in Cancer Multidrug Resistance
Pavlíková, L., Šereš, M., Breier, A., & Sulová, Z. (2022) · Cancers · doi:10.3390/cancers14041090 · Cited by 54 · see citing works
MicroRNA-21 controls hTERT via PTEN in human colorectal cancer cell proliferation
Yang, Y., Yang, J., Tao, H., & Jin, W.-S. (2015) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-015-0380-5 · Cited by 48 · see citing works
Revisiting chemoresistance in ovarian cancer: Mechanism, biomarkers, and precision medicine
Guo, C., Song, C., Zhang, J., Gao, Y., Qi, Y., Zhao, Z., & Yuan, C. (2020) · Genes & Diseases · doi:10.1016/j.gendis.2020.11.017 · Cited by 47 · see citing works
Epigenetic alternations and cancer chemotherapy response
Lv, J., Hu, L., Zhuo, W., Zhang, C., Zhou, H., & Fan, L. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2951-0 · Cited by 46 · see citing works
Fan, B., Jin, Y., Zhang, H., Zhao, R., Sun, M., Sun, M., Yuan, X.-Y., Wang, W., Wang, X., Chen, Z., et al. (2019) · International Journal of Oncology · doi:10.3892/ijo.2019.4928 · Cited by 46 · see citing works
miR-21: A Key Small Molecule with Great Effects in Combination Cancer Therapy
Arghiani, N., & Matin, M. M. (2021) · Nucleic Acid Therapeutics · doi:10.1089/nat.2020.0914 · Cited by 46 · see citing works
miRNAs and ovarian cancer: a miRiad of mechanisms to induce cisplatin drug resistance
Samuel, P., Pink, R. C., Brooks, S. A., & Carter, D. R. F. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2016.1121107 · Cited by 44 · see citing works
He, T., Shen, H., Wang, S., Wang, Y., He, Z., Zhu, L., Du, X., Wang, D., Li, J., Zhong, S., et al. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.09.024 · Cited by 41 · see citing works
He, W., Wang, C., Mu, R., Liang, P., Huang, Z., Zhang, J., & Dong, L. (2017) · Oncogene · doi:10.1038/onc.2017.62 · Cited by 42 · see citing works
Tao, Y., Li, Y., Zheng, W., Zhao, J., Guo, M., Zhou, Y., Qin, N., Zheng, J., & Xu, L. (2015) · Cancer Cell International · doi:10.1186/s12935-015-0228-7 · Cited by 39 · see citing works
Small Non-Coding-RNA in Gynecological Malignancies
Dwivedi, S. K. D., Rao, G., Dey, A., Mukherjee, P., Wren, J. D., & Bhattacharya, R. (2021) · Cancers · doi:10.3390/cancers13051085 · Cited by 39 · see citing works
Hu, Y., Wang, C., Li, Y., Zhao, J., Chen, C., Zhou, Y., Tao, Y., Guo, M., Qin, N., Ren, T., et al. (2015) · Immunology and Cell Biology · doi:10.1038/icb.2015.37 · Cited by 38 · see citing works
Schmidtova, S., Dorssers, L. C. J., Kaľavská, K., Gillis, A., Oosterhuis, J. W., Stoop, H., Miklikova, S., Kozovská, Z., Buríková, M., Gercakova, K., et al. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01458-7 · Cited by 37 · see citing works
Oleuropein reduces cisplatin resistance in ovarian cancer by targeting apoptotic pathway regulators
Sheikhshabani, S. H., Amini‐Farsani, Z., Rahmati, S., Jazaeri, A., Mohammadi-Samani, M., & Asgharzade, S. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119525 · Cited by 36 · see citing works
Downregulation of miR-21 as a promising strategy to overcome drug resistance in cancer
Akhtarkhavari, T., Bahrami, A. R., & Matin, M. M. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175233 · Cited by 35 · see citing works
Qi, X., Yu, C., Wang, Y., Lin, Y., & Shen, B. (2019) · Clinical and Translational Medicine · doi:10.1186/s40169-019-0245-6 · Cited by 34 · see citing works
Arısan, E. D., Rencüzoğulları, Ö., Freitas, I. L., Radzali, S., Keskin, B., Kothari, A., Warford, A., & Onganer, P. U. (2020) · Biology · doi:10.3390/biology9030052 · Cited by 35 · see citing works
Metabolic Remodeling as a Way of Adapting to Tumor Microenvironment (TME), a Job of Several Holders
Serpa, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-34025-4_1 · Cited by 34 · see citing works
Mechanisms of the JNK/p38 MAPK signaling pathway in drug resistance in ovarian cancer
Ma, Y., Li, C., Shen, Y., Wan-hui, Y., Han, M.-X., Mu, Y.-F., & Han, F. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1533352 · Cited by 33 · see citing works
Dou, Y., Jiang, X., Xie, H., He, J., & Xiao, S. (2019) · Journal of Ovarian Research · doi:10.1186/s13048-019-0573-6 · Cited by 33 · see citing works
Modulation of chemoresponsiveness to platinum-based agents by microRNAs in cancer.
Yu, X., Zheng, H., Chan, M. T. V., & Wu, W. K. K. (2017) · Europe PMC (PubMed Central) · Cited by 33 · see citing works
Wang, Y., Chen, G., Dai, F., Zhang, L., Yuan, M., Yang, D., Liu, S., & Cheng, Y. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s286639 · Cited by 32 · see citing works
Boric acid as a promising agent in the treatment of ovarian cancer: Molecular mechanisms
Çabuş, Ü., Seçme, M., Kabukçu, C., Çil, N., Dodurga, Y., Mete, G. A., & Fenkçi, İ. V. (2021) · Gene · doi:10.1016/j.gene.2021.145799 · Cited by 32 · see citing works
Wang, Z., Zhou, H., Cheng, F., Zhang, Z., & Long, S. (2022) · Digestive and Liver Disease · doi:10.1016/j.dld.2022.04.007 · Cited by 32 · see citing works
Rivera‐Díaz, M., Miranda-Román, M. A., Soto, D., Quintero-Aguilo, M., Ortiz‐Zuazaga, H., Marcos-Martínez, M. J., & Vivas‐Mejía, P. E. (2015) · Europe PMC (PubMed Central) · Cited by 32 · see citing works
Self-citationLi, G., Song, Y., Li, G., Ren, J., Xie, J., Zhang, Y., Gao, F., Mu, J., & Dai, J. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9255 · Cited by 31 · see citing works
Quiñones‐Díaz, B. I., Reyes‐González, J. M., Guzmán, V. S., Moral, I. C.-D., Valiyeva, F., Santiago-Sánchez, G. S., & Vivas‐Mejía, P. E. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.602670 · Cited by 31 · see citing works
Self-citationJavanmardi, S., Tamaddon, A. M., Aghamaali, M. R., Ghahramani, L., & Abolmaali, S. S. (2018) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2018.10.006 · Cited by 30 · see citing works
Zhang, H., Li, J., Li, G., & Wang, S. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5894 · Cited by 29 · see citing works
Wang, Y., Yang, X., Yuan, M., Xian, S., Zhang, L., Yang, D., & Cheng, Y. (2019) · Oncology Reports · doi:10.3892/or.2019.7153 · Cited by 29 · see citing works
Flavonoid display ability to target microRNAs in cancer pathogenesis
Singh, S., Raza, W., Parveen, S., Meena, A., & Luqman, S. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114409 · Cited by 29 · see citing works
Targeting MicroRNA-143 Leads to Inhibition of Glioblastoma Tumor Progression
Lozada-Delgado, E. L., Grafals‐Ruiz, N., Miranda-Román, M. A., Santana‐Rivera, Y., Valiyeva, F., Rivera‐Díaz, M., Marcos-Martínez, M. J., & Vivas‐Mejía, P. E. (2018) · Cancers · doi:10.3390/cancers10100382 · Cited by 29 · see citing works
Self-citationImpact of Nutrition on Non-Coding RNA Epigenetics in Breast and Gynecological Cancer
Krakowsky, R. H. E., & Tollefsbol, T. O. (2015) · Frontiers in Nutrition · doi:10.3389/fnut.2015.00016 · Cited by 25 · see citing works
Pang, L., Lu, J., Huang, J., Xu, C., Li, H., Yuan, G., Cheng, X., & Chen, J. (2017) · Oncology Letters · doi:10.3892/ol.2017.7242 · Cited by 25 · see citing works
CEA, CA 15-3, and miRNA expression as potential biomarkers in canine mammary tumors
Jain, M., Ingole, S. D., Deshmukh, R. S., Bharucha, S. V., Nagvekar, A. S., Gaikwad, R. V., & Kharde, S. D. (2021) · Chromosome Research · doi:10.1007/s10577-021-09652-7 · Cited by 24 · see citing works
Kong, Q., Wang, W., & Li, P. (2015) · PubMed Central · Cited by 23 · see citing works
miR-21-5p Inhibits the Proliferation, Migration, and Invasion of Glioma by Targeting S100A10
Gao, P., Wang, H., Li, H., Shu, L., Han, Z., Li, S., Cheng, H., & Dai, X. (2023) · Journal of Cancer · doi:10.7150/jca.84030 · Cited by 22 · see citing works
Liu, J., Zhai, R., Zhao, J., Kong, F., Wang, J., Jiang, W., Xin, Q., Xue, X., & Luan, Y. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4303 · Cited by 21 · see citing works
The Ratio of Toxic-to-Nontoxic miRNAs Predicts Platinum Sensitivity in Ovarian Cancer
Patel, M., Wang, Y., Bartom, E. T., Dhir, R., Nephew, K. P., Matei, D. E., Murmann, A. E., Lengyel, E. R., & Peter, M. E. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0953 · Cited by 20 · see citing works
Wu, D., Shi, M., & Fan, X. (2015) · Asian Pacific Journal of Tropical Medicine · doi:10.1016/j.apjtm.2015.05.003 · Cited by 20 · see citing works
Downstream Effectors of ILK in Cisplatin-Resistant Ovarian Cancer
Reyes‐González, J. M., Quiñones‐Díaz, B. I., Santana‐Rivera, Y., Báez, P., Soto, D., Valiyeva, F., Marcos-Martínez, M. J., Thomas, R. J. F.-D., & Vivas‐Mejía, P. E. (2020) · Cancers · doi:10.3390/cancers12040880 · Cited by 19 · see citing works
Self-citationMicroRNA-21 in gynecological cancers: From molecular pathogenesis to clinical significance
Jiang, N.-J., Yin, Y., Lin, J., Li, W., Long, D.-R., & Mei, L. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154630 · Cited by 18 · see citing works
Boric Acid Affects Cell Proliferation, Apoptosis, and Oxidative Stress in ALL Cells
Hilal, B., Eldem, A., Öz, T., Pehli̇van, M., & Pirim, İ. (2023) · Biological Trace Element Research · doi:10.1007/s12011-023-03958-9 · Cited by 18 · see citing works
Masroor, M., Guru, S. A., Abdullah, S. M., Rizvi, A., & Saxena, A. (2019) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2019.20.8.2379 · Cited by 16 · see citing works
Lactylation-mediated miRNA regulation in cancer therapy resistance
Shou, Y., Liu, R., Xiong, H., Chen, X., Huang, L., Huang, R., Sheng, H., Zhang, H., Lu, Y., & Guo, H. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06959-5 · Cited by 15 · see citing works
Liang, X., & Jian-xin, J. (2021) · Oncology Reports · doi:10.3892/or.2021.8033 · Cited by 15 · see citing works
RetractedRivera, R. A. N., Rivera, M., Rabelo-Fernández, R. J., Pérez‐Santiago, J., Valiyeva, F., & Vivas‐Mejía, P. E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147737 · Cited by 15 · see citing works
Self-citationHan, Y., Li, Q., Ling, C., Jin, M., Li, D., Zhong, J., & Wang, L. (2022) · Contrast Media & Molecular Imaging · doi:10.1155/2022/6297694 · Cited by 15 · see citing works
Rabelo-Fernández, R. J., Santiago-Sánchez, G. S., Sharma, R. K., Roche-Lima, A., Carrasquillo, K., Rivera, R. A. N., Quiñones‐Díaz, B. I., Rajasekaran, S., Siddiqui, J., Miles, W. O., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23010535 · Cited by 14 · see citing works
Self-citationSmad3 Sensitizes Hepatocelluar Carcinoma Cells to Cisplatin by Repressing Phosphorylation of AKT
Zhou, H., Chen, L., Liang, H., Li, G., Zhang, B., & Chen, X. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17040610 · Cited by 14 · see citing works
Drakopoulou, E., Anagnou, N. P., & Pappa, K. I. (2022) · Cancers · doi:10.3390/cancers14133238 · Cited by 13 · see citing works
Interactions between anticancer active platinum complexes and non-coding RNAs/microRNAs
Biersack, B. (2016) · Non-coding RNA Research · doi:10.1016/j.ncrna.2016.10.001 · Cited by 12 · see citing works
Double Insurance for OC: miRNA-Mediated Platinum Resistance and Immune Escape
Zou, X., Zhao, Y., Liang, X., Wang, H., Zhu, Y., & Shao, Q. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.641937 · Cited by 12 · see citing works
Javanmardi, S., Abolmaali, S. S., Mehrabanpour, M., Aghamaali, M. R., & Tamaddon, A. M. (2022) · Bioimpacts · doi:10.34172/bi.2022.23263 · Cited by 12 · see citing works
Zhu, H., Lan, L., Zhang, Y., Chen, Q., Zeng, Y., Luo, X., Ren, J., Chen, S., Xiao, M., Lin, K., et al. (2020) · The FASEB Journal · doi:10.1096/fj.201900847rrrr · Cited by 12 · see citing works
Immune cell-derived extracellular vesicular microRNAs induce pancreatic beta cell apoptosis
Yu, Y., Li, M., Zhao, Y., Fan, F., Wu, W., Gao, Y., & Bai, C. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e11995 · Cited by 11 · see citing works
Arsenic activates STAT3 signaling during the transformation of the human bronchial epithelial cells
Almutairy, B. S., Fu, Y. S., Bi, Z., Zhang, W., Wadgaonkar, P., Qiu, Y., Thakur, C., & Chen, F. (2022) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2022.115884 · Cited by 11 · see citing works
Unlocking the Therapeutic Potential of Plant Extracts
Lundstrom, K. H. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2015-0012 · Cited by 11 · see citing works
Ravegnini, G., Iaco, P. D., Gorini, F., Dondi, G., Klooster, I., Crescenzo, E. D., Bovicelli, A., Hrelia, P., Perrone, A. M., & Angelini, S. (2021) · Biomedicines · doi:10.3390/biomedicines9101316 · Cited by 10 · see citing works
Clinical significance of miRNA-21, -103, -129, -150 in serous ovarian cancer
Wilczyński, M., Żytko, E., Danielska, J., Szymańska, B., Dzieniecka, M., Nowak, M., Malinowski, J., Owczarek, D., & Wilczyński, J. R. (2018) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-018-4660-5 · Cited by 10 · see citing works
Mutually distinguishing microRNA signatures of breast, ovarian and endometrial cancers in�vitro
Hirschfeld, M., Ge, I., Rücker, G., Waldschmidt, J., Mayer, S., J�ger, M., Voigt, M., Kammerer, B., N�thling, C., Berner, K., et al. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11466 · Cited by 10 · see citing works
MicroRNA‑mediated approaches in ovarian cancer therapy: A comprehensive systematic review
Putri, H. M. A. R., Novianti, P. W., Pradjatmo, H., & Haryana, S. M. (2024) · Oncology Letters · doi:10.3892/ol.2024.14624 · Cited by 9 · see citing works
Gene Selection for the Discrimination of Colorectal Cancer
Wang, W., Xie, G., Ren, Z., Xie, T., & Li, J. (2019) · Current Molecular Medicine · doi:10.2174/1566524019666191119105209 · Cited by 9 · see citing works
Kim, G., Bhattarai, P. Y., & Choi, H. S. (2019) · Archives of Pharmacal Research · doi:10.1007/s12272-019-01122-3 · Cited by 9 · see citing works
MiRNAs related in signaling pathways of women’s reproductive diseases: an overview
Bagheri, M., Khansarinejad, B., Mondanizadeh, M., Azimi, M., & Alavi, S. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-09357-0 · Cited by 8 · see citing works
The Role of microRNAs in Arsenic-Induced Human Diseases: A Review
Liu, Q., & Lei, Z. (2023) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.3c03721 · Cited by 7 · see citing works
Wilczyński, J. R., Paradowska, E., Wilczyńska, J., & Wilczyński, M. (2023) · Current Oncology · doi:10.3390/curroncol31010015 · Cited by 7 · see citing works
Ferreira, M., Morais, M., Medeiros, R., & Teixeira, A. L. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16111347 · Cited by 7 · see citing works
Premature MicroRNA-Based Therapeutic: A “One-Two Punch” against Cancers
Chen, L., Huang, K., Yi, K., Huang, Y., Tian, X., & Kang, C. (2020) · Cancers · doi:10.3390/cancers12123831 · Cited by 7 · see citing works
Is miR therapeutic targeting still a miRage?
Levantini, E. (2021) · Frontiers in Bioscience-Landmark · doi:10.52586/4979 · Cited by 7 · see citing works
Rabelo-Fernández, R. J., Rivera, R. A. N., Santana‐Rivera, Y., Tous-Beveraggi, J., Valiyeva, F., & Vivas‐Mejía, P. E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314742 · Cited by 6 · see citing works
Self-citationWei, S., Liu, J., Shi, Y., Zhang, X., Yang, Y., & Song, Q. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.7008 · Cited by 5 · see citing works
Kumar, S., Sisodiya, S., Rani, J., Shah, P., Yadav, C. P., Shah, K., Gupta, B., Hussain, S., & Singh, S. (2025) · Journal of Ovarian Research · doi:10.1186/s13048-025-01836-7 · Cited by 4 · see citing works
Cancer and Developmental Origins of Health and Disease—Epigenetic Reprogramming as a Mediator
Ho, S., Cheong, A. W. Y., To, S. Q., Janakiram, V., Tarapore, P., & Leung, Y. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801383-0.00016-5 · Cited by 4 · see citing works
RETRACTED: Enhancing wound healing and overcoming cisplatin resistance in ovarian cancer
ZHANG, Q.-F., Guo, F., Liu, H., & Li, H. (2023) · International Wound Journal · doi:10.1111/iwj.14569 · Cited by 3 · see citing works
RetractedCorrection: Upregulation of miR-21 in Cisplatin Resistant Ovarian Cancer via JNK-1/c-Jun Pathway
Staff, T. P. O. (2014) · PLoS ONE · doi:10.1371/journal.pone.0116447 · Cited by 3 · see citing works
- Authors
- Echevarría-Vargas, I. M., Valiyeva, F., & Vivas-Mejía, P. E.
- Affiliations
- University of Puerto Rico, Medical Sciences Campus (PR)
- University of Puerto Rico System (PR)
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-05-27
- Volume
- 9
- Issue
- 5
- Pages
- e97094
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4035252
- OpenAlex
- W2077670883
- Cited by
- 118
- References
- 53
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 6 · 2023: 13 · 2022: 14 · 2021: 13 · 2020: 12 · 2019: 10 · 2018: 8 · 2017: 8 · 2016: 8 · 2015: 16 · 2014: 2
- FWCI
- 3.63
- Type
- journal article
- Language
- en
- Update notices
- correction (2014-12-26)
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- National Institutes of Health
- National Cancer Institute (K22CA166226)
- National Institute of General Medical Sciences (R25GM061838)
- National Institute on Minority Health and Health Disparities (U54MD008149)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Health Sciences › Medicine › Reproductive Medicine › Ovarian cancer diagnosis and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
- Keywords
- miR-21, cisplatin resistance, ovarian cancer, JNK1, c-Jun, JNK/c-Jun signaling pathway, PDCD4, microRNA regulation, cell proliferation, cell invasion, drug resistance
- MeSH terms
- Antineoplastic Agents, Cell Movement, Cisplatin, Female, Humans, Ovarian Neoplasms, Promoter Regions, Genetic, RNA, Messenger, Tumor Cells, Cultured, Blotting, Western, RNA-Binding Proteins, Apoptosis, Drug Resistance, Neoplasm, Reverse Transcriptase Polymerase Chain Reaction, Chromatin Immunoprecipitation, JNK Mitogen-Activated Protein Kinases, Mitogen-Activated Protein Kinase 8, Cell Proliferation, Apoptosis Regulatory Proteins, Real-Time Polymerase Chain Reaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
